Evaluation of Innovation Efficiency of Listed Biopharmaceutical Enterprises based on Three-Stage Data Envelopment Analysis / 医药导报

Objective To provide a reference for biopharmaceutical enterprises in China to improve innovation efficiency and the government to formulate relevant policies.Methods Research and development-related data and regional environmental data of 32 listed biopharmaceutical companies from 2015 to 2021 were selected to measure the innovation efficiency of listed biopharmaceutical companies with the three-stage data envelopment analysis(DEA)model,excluding the impact of environmental factors and random disturbances.Results After excluding the impact of environmental factors and random disturbances,the average innovation efficiency of listed biopharmaceutical enterprises was 0.46.The average pure technology efficiency and scale efficiency were 0.99 and 0.46,respectively.The regression coefficients among economic development level,government support intensity,degree of competition,opening-up level,and the slack value of R & D personnel were 185.97(P＜0.05),105.67(P＞0.10),385.81(P＜0.01),-121.64(P＜0.05),respectively.The regression coefficients between economic development level,government support,degree of competition,opening-up level,and the slack value of R & D investment were 136.13(P＞0.10),258.61(P＜0.01),285.33(P＜0.01),-30.52(P＞0.10),respectively.Conclusion The innovation efficiency of listed biopharmaceutical enterprises in China is at a relatively low level.Scale efficiency is the main factor restricting the improvement of innovation efficiency.The regional opening-up level contributes to the improvement of innovation efficiency of listed biopharmaceutical companies,while the level of competition,government support and economic development level constrain improvements in innovation efficiency.The external environment hinders the improvement of the concentration degree of the biopharmaceutical industry,which hurts exerting the scale effect for enterprises.

Research on the technological innovation efficiency of Chinese listed biopharmaceutical enterprises based on the two-stage DEA model / 中国药房

OBJECTIVE To provide reference for improving the techn ological innovation efficiency of biopharmaceutical enterprises in China. METHODS In this research ，the technological innovation process of the biopharmaceutical enterprises was divided into two stages ：the technological development and the achievement transformation. Two-stage data envelopment analysis （DEA） model was established under the premise of considering the two-stage correlation ，and the two-stage technological innovation efficiency of 23 listed biopharmaceutical enterprises in China was evaluated from 2016 to 2020 on the basis of hysteresis effect. RESULTS & CONCLUSIONS The two-stage technological innovation efficiency of listed biopharmaceutical enterprises in China was at a relatively low level ，and the average overall efficiency of the technological development stage and the achievement transformation stage were only 0.377 and 0.347. At present ，the low efficiency of technology is the main factor restricting the improvement of the two-stage technological innovation efficiency of listed biopharmaceutical enterprises in China. In the technology development stage ，redundant investment in R&D funds and insufficient patent output are the main reasons for the invalid DEA of listed biopharmaceutical enterprises ，while in the achievement transformation stage ，the redundant input of invention patents is the main reason for the invalid DEA of listed biopharmaceutical enterprises. From a regional perspective ，in the technology development stage ，the average overall efficiency and technical efficiency of listed biopharmaceutical enterprises in the eastern region are 0.378 and 0.603，which are higher than the central and western regions. In the stage of achievement transformation，the average values of comprehensive efficiency and technical efficiency of listed biopharmaceutical enterprises in the central and western regions are 0.361 and 0.548，which are higher than those in the eastern region. It is suggested that biopharmaceutical enterprises should enhance their ability to transform technological achievements ，optimize the allocation of scientific and technological resources ，attach importance to （No.2021GXJK332） regional cooperation and exchanges ， promote the overall innovation efficiency of biopharmaceutical industry in China.

The Present Situation and Countermeasures for Continuous Technological Innovation of Biopharmaceutical Enterprises in China / 中国药房

OBJECTIVE:To provide reference information for continuous technological innovation of biopharmaceutical enterprises in China.METHODS:Based on theory of continuous technological innovation,we summarized the present situation of technological innovation in China's biopharmaceutical enterprises and analyzed the problems through the way of SWOT;fina lly we put forward the countermeasures.RESULTS&CONCLUSION:If biopharmaceutical enterprises want to develop and grow,they must unite related departments to construct the system of continuous technological innovation.